Precision BioSciences, Inc. (DTIL)

Over the past six months, Precision BioSciences' stock price has increased by 84.9% year-to-date as of May 9, 2026, trading at $7.69. Key events include raising $75 million in November 2025, receiving FDA Fast Track designation for PBGENE-DMD in March 2026, activating the first clinical trial site for PBGENE-DMD in April 2026, and reporting Q1 2026 revenues of $10.8 million in May 2026.

As a clinical-stage biotechnology company focused on research and development of therapeutic products that are not yet commercially available, there is no information available regarding demand seasonality for its products and services.

Precision BioSciences is a clinical-stage gene editing company headquartered in Durham, North Carolina, focused on improving life through its ARCUS® genome editing platform. The company's pipeline focuses on developing in vivo gene editing therapies for genetic and infectious diseases with high unmet medical needs, including PBGENE-HBV for chronic hepatitis B virus, PBGENE-DMD for Duchenne muscular dystrophy, PBGENE-3243 for m.3243 associated mitochondrial diseases, and iECURE-OTC for ornithine transcarbamylase deficiency.

Precision BioSciences is headquartered in Durham, North Carolina, United States, and its clinical trials have a global reach. The ELIMINATE-B clinical trial for PBGENE-HBV has expanded into Europe, with sites in the United Kingdom, Moldova, France, and Romania, in addition to existing sites in New Zealand, Hong Kong, and the United States. The iECURE-OTC study is ongoing in the U.K., the U.S., Australia, and Spain.

Precision BioSciences' brand reputation has been positively influenced by its advancements in clinical trials and regulatory milestones. Positive events include receiving FDA Fast Track designation for PBGENE-DMD, activating the first clinical trial site for the Phase 1/2 FUNCTION-DMD study, expanding the ELIMINATE-B clinical trial for PBGENE-HBV into new European countries, and presentations of preclinical and clinical data at major scientific conferences.

Precision BioSciences, Inc. has a significant portion of its shares held by institutional investors, ranging from 47.64% to 83% of the shares outstanding. Major institutional shareholders include Standard Life Aberdeen plc, Empery Asset Management, LP and Vanguard Group Inc. Individual and insider ownership ranges from 2.70% to 4.46% of the stock.